Navigation Links
DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
Date:6/3/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., June 3, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced that the company presented a poster entitled "Phase I/II Study of VAL-083 (dianhydrogalactitol) in Patients with Recurrent Malignant Glioma or Progressive Secondary Brain Tumor" at the American Society of Clinical Oncology (ASCO) Annual Meeting, on June 1, 2013 in Chicago.

DelMar presented additional clinical data from the company's ongoing Phase I/II clinical trial with VAL-083.  The trial is a dose-escalation study designed to assess the safety and activity of VAL-083 as a potential treatment for brain cancer patients suffering from glioblastoma or secondary-progressive brain tumor who have failed standard therapies and have no viable treatment options. Three cohorts of patients have been enrolled so far, testing VAL-083 at 1.5mg/m2; 3.0mg/m2 and 5.0mg/m2.  A link to the company's poster can be found at: http://www.delmarpharma.com/DelMarASCO2013-11x17.pdf

Jeffrey Bacha , president & CEO of DelMar Pharmaceuticals, noted, "These new data presented at ASCO continue to demonstrate promise for VAL-083 as a potential treatment for cancer patients suffering from GBM as well as patients who are suffering from other cancers that have spread to the brain. Tumors of the brain are among the most challenging malignancies to treat. Median survival for patients with recurrent disease is approximately 6 months for glioblastoma multiforme.  Central nervous system metastases have evolved as a major contributor to cancer mortality because many new systemic therapies cannot reach tumors spreading to the brain."

Highlights of the DelMar ASCO
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
2. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
3. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
4. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
5. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
6. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
7. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
8. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
9. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
10. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
11. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 26, 2014  Over 100 million adults suffer ... from this pain daily. Chronic and acute pain dramatically ... is born to fulfill the need for non-surgical, interventional ... pain. On October 28th, a new pain ... Cumberland, Maryland community.  This new facility boasts ...
(Date:11/26/2014)...  BioScrip ® , Inc. (NASDAQ: BIOS ) announced ... Officer, will present at the Bank of America Merrill Lynch 2014 ... Date: , , , Wednesday, December 3, 2014 , , ... , , , Location: , , , Boca Raton Resort and ... BioScrip, Inc. is a leading national provider ...
(Date:11/26/2014)... a leader in the development of Chimeric Antigen Receptors ... cancers, today announced the completion of a series A ... -based healthcare private equity fund.   CARsgen ... new therapeutics for liver, lung, stomach and brain cancers. ... Hospital, the company plans to initiate clinical studies for ...
Breaking Medicine Technology:New Pain Management Center Opens in Cumberland, Md. 2CARsgen Completes Series A Financing 2
... AdvanDx today announced the FDA,510(k) submission of ... of,Candida yeast species from positive blood cultures. ... AdvanDx,s easy-to-use, molecular-based PNA,FISH(TM) diagnostics platform that ... instead of days. Candidemia, a bloodstream,infection caused ...
... FORT WORTH, Texas, June 3 Wound Care,Innovations, ... MB Software Corporation (OTC Bulletin Board: MBSB)) announced,today ... evaluating the clinical,performance of their advanced wound care ... a major problem in the elderly and,compromised patients. ...
Cached Medicine Technology:AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures 2AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures 3Wound Management Technologies, Inc. Announces Evidence Based Study 2
(Date:11/28/2014)... Now that the holiday season is here, ... nation's leading cash-for-junk-cars companies, is improving their cash offers ... competitive and help bring a little bit more joy ... year. , Along with purchasing expensive gifts for family ... deal with large travel expenses during the holiday season. ...
(Date:11/28/2014)... November 28, 2014 Novatus, a ... its Release v5.1 which provides customers with greater ... options. , “As we continue to evolve ... provide more functionality and improved performance in response ... CEO for Novatus. “With the enhancements that we ...
(Date:11/28/2014)... Wisconsin (PRWEB) November 28, 2014 Dr. ... plastic surgeons , announced the expansion of Quintessa Aesthetic ... center will be located at W307 N1497 Golf Road ... , According to Dr. Campbell, the new Delafield location ... procedures for patients, including: Botox, filler injectables ...
(Date:11/28/2014)... Texas (PRWEB) November 28, 2014 Dr. Paul Vitenas, ... will hold a Glitter & Glow Holiday Event for those in ... treatments offered at his practice. Glitter & Glow will take place ... Dr. Vitenas’ new location in the heart of Houston at 4208 ... of holidays and hope that you will come and celebrate the ...
(Date:11/28/2014)... Written and narrated by award winning author ... “The Happiest Man In the World: Life Lessons From ... and why Project C.U.R.E. came to be. , Raised in ... the Reverend Richard W. Jackson, Dr. Jackson exceeded his goal ... realized that he wasn’t happy. Prompted by this realization, James ...
Breaking Medicine News(10 mins):Health News:Rusty's Auto Salvage Increasing Their Cash Offers to Help Drivers Save Throughout the Busy Holiday Season 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2
... Christmas Programs and Next Year,s Services , ... in Chicago is facing a grave financial shortfall which will ... pace of donations increases this Christmas season according to its ... , "The economic downturn has attacked us ...
... of millions of people, mainly in developing countries, are ... Organization. , More than 12 million people in ... spread by the bite of infected sand flies. Nearly ... people die from the disease annually. , Researchers ...
... high-energy diet pill really save your job? It seems that ... and other retailers are seeing a significant drop in sales ... is reporting dramatically increased sales of Zantrex-3 (R), their ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081216/LA52707 ) , , ...
... in mucus could fight deadly,bacteria in lungs , , TUESDAY, ... that stain the mucus in the lungs of cystic ... infections, researchers say. , The pigments may enable infectious ... communities, according to a Massachusetts Institute of Technology (MIT) ...
... that they know. Or maybe not. A new study published in Human ... human genome must pay attention to ancestry when analyzing and interpreting their ... ... someone where their ancestors were from and odds are that they know. ...
... Health (NIH) has awarded nearly $3 million to support Rush ... the health outcomes and health care cost savings for very ... , The grant will enable researchers at Rush to ... 600 very low birth weight infants born to racially and ...
Cached Medicine News:Health News:Salvation Army Services Threatened by Pace of Donations 2Health News:UIC researchers hunting drugs for devastating parasitic disease 2Health News:Sales of Energy-Boosting Diet Pills Skyrocket as the Economy Falters 2Health News:Scientists Spot Key to Cystic Fibrosis Infections 2Health News:Genome-wide Association Studies Must Account for Ancestry 2Health News:Genome-wide Association Studies Must Account for Ancestry 3Health News:Study examines how breastfeeding impacts cost of care for very low birth weight infants 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: